Scholar Rock Reports Third Quarter 2018 Financial Results and Highlights Business Progress


Scholar Rock, a biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial 

We continue to make important progress with our pipeline having now completed enrollment in the multiple ascending dose portion of the ongoing Phase 1 clinical trial for SRK-015 with interim results and the initiation of a Phase 2 proof-of-concept study in patients with Spinal Muscular Atrophy (SMA) presentation of preclinical data at the SITC annual meeting that will demonstrate the ability of a highly specific inhibitor of TGF1 to render resistant solid Quarter of 2019. A placebo-controlled, double-blind Phase 1 clinical trial was initiated in May 2018 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of intravenous SRK-015, a selective inhibitor of the activation of …

[Read on via official release]

Source: US SEC
View full document: